济民药业,关爱无限 www.pidrug.com
香港济民药业微信二维码
198 9654 1773
当前位置:首页 > 药品资讯 > 精神科 > 托吡酯Topamax

托吡酯Topamax

[ 人气:118 | 日期: 2020-08-04 | 返回 | 打印 ]
托吡酯Topamax
药品名称:托吡酯Topamax
药品别名:妥泰(Topiramate,Topamax)
英 文 名:Topamax
药品价格:$ 美国市场售价 4.1 美元
研发公司:
适 用 症:适用于用于伴有或不伴有继发性全身发作的部分性癫痫发作的加用治疗。
型号规格:片剂,每片含有效成份25mg/50mg/100mg,每瓶15片装。
药品详情:

【托吡酯Topamax 简述】
 
    托吡酯又名妥泰(Topiramate,Topamax)是一新型抗癫痫药物。

托吡酯Topamax_香港济民药业
 
【托吡酯Topamax 适应症】
 
    本品适用于用于伴有或不伴有继发性全身发作的部分性癫痫发作的加用治疗。
 
【托吡酯Topamax 规格】
 
    本品为片剂,每片含有效成份25mg/50mg/100mg,每瓶15片装。
 
【托吡酯Topamax 服用方法】
 
    推荐的用量为,每日2次,每天200至400mg。具体用药请咨询主治医师。
 
【托吡酯Topamax 注意事项】
 
    已知对本品过敏者禁用。包括本药在内的抗癫痫药物应逐渐停药,以使癫痫发作频率增高的可能性减至最低。在临床试验中,每周减量100 mg/日。某些病人在无并发症的情况下,停药过程可加速。原型托吡酯及其代谢产物的主要排泄途径为肾脏清除,肾脏清除的能力与肾脏的功能有关,而与年龄无关,伴有中度或重度肾功能损害的患者达到稳态血浆浓度的时间可能需10-15天,而肾功能正常的患者只需4-8天。与所有患者一样,剂量调整应根据临床疗效进行(如对癫痫发作的控制、副作用的发生),并且需了解对于已知有肾脏损害的患者,在每个剂量下达到稳态血浆浓度的时间均需延长。
 
【托吡酯Topamax 不良反应】
 
    最常见的不良反应主要为与中枢神经系统相关的症状,包括:共济失调、注意力受损、意识模糊、头晕、疲劳、感觉异常、嗜睡和思维异常。不常见的不良反应包括焦虑、遗忘、食欲不振、失语、忧郁、复视、情绪不稳、恶心、眼球震颤、言语表达障碍、味觉倒错、视觉异常和体重减轻。罕见肾石症的报道。有个例血栓栓塞的报道,其与药物间的相关性不明确。

Topamax(Topiramate)

 
Topiramate, sold under the brand name Topamax among others, is a medication used to treat epilepsy and prevent migraines.[1] It has also been used in alcohol dependence.[1] For epilepsy this includes with generalized or focal seizures.[2] It is taken by mouth.[1]
 
Common side effects include tingling, loss of appetite, feeling tired, abdominal pain, hair loss, and trouble concentrating.[1][2] Serious side effects may include suicide, increased ammonia levels resulting in encephalopathy, and kidney stones.[1] Use in pregnancy may result in harm to the baby and use during breastfeeding is not recommended.[3] How it works is unclear.[1]
 
Topiramate was approved for medical use in the United States in 1996.[1] It is avaliable as a generic medication.[2] A month supply in the United Kingdom costs the NHS about 1.40 £ per month as of 2019.[2] In the United States the wholesale cost of this amount is about 4.00 USD.[4]
 
Medical uses
 
Topiramate is used to treat epilepsy in children and adults, and it was originally used as an anticonvulsant.[5] In children, it is indicated for the treatment of Lennox-Gastaut syndrome, a disorder that causes seizures and developmental delay. It is most frequently prescribed for, the prevention of migraines.[5] It decreases the frequency of attacks.[6][7]
Pain
A 2018 review found topiramate of no use in chronic low back pain.[8] Topiramate has not been shown to work as a pain medicine in diabetic neuropathy, the only neuropathic condition in which it has been adequately tested.[9]
Other
One common off-label use for topiramate is in the treatment of bipolar disorder.[10][11][12] A review published in 2010 suggested a benefit of topiramate in the treatment of symptoms of borderline personality disorder, however the authors noted that this was based only on one randomized controlled trial and requires replication.[13]
Topiramate has been used as a treatment for alcoholism.[14] The VA/DoD 2015 guideline on substance use disorders lists topiramate as a "strong for" in its recommendations for alcohol use disorder.[15]
 
Other uses include treatment of obesity[16][17] and antipsychotic-induced weight gain.[18][19] It is being studied to treat post traumatic stress disorder.[20] In 2012, the combination phentermine/topiramate was approved in the United States for weight loss.
  
Adverse effects
 
People taking topiramate should be aware of the following risks:
§  Avoid activities requiring mental alertness and coordination until drug effects are realized.
§  Topiramate may impair heat regulation,[21] especially in children. Use caution with activities leading to an increased core temperature, such as strenuous exercise, exposure to extreme heat, or dehydration.
§  Topiramate may cause visual field defects.[22]
§  Topiramate may decrease effectiveness of oestrogen-containing oral contraceptives.
§  Taking topiramate in the 1st trimester of pregnancy may increase risk of cleft lip/cleft palate in infant.[23]
§  As is the case for all antiepileptic drugs, it is advisable not to suddenly discontinue topiramate as there is a theoretical risk of rebound seizures.
 
Frequency
 
Adverse effects by incidence:[24][25][26][27]
 
Very common (>10% incidence) adverse effects include:
 
§  Dizziness
§  Weight loss
§  Paraesthesia - e.g., pins and needles
§  Somnolence
§  Nausea
§  Diarrhea
§  Fatigue
§  Nasopharyngitis
§  Depression
 
Uncommon (1-10% incidence) adverse effects include:
 
§  Weight gain
§  Anaemia
§  Disturbance in attention
§  Memory impairment
§  Amnesia
§  Cognitive disorder
§  Mental impairment
§  Psychomotor skills impaired
§  Convulsion
§  Coordination abnormal
§  Tremor
§  Lethargy
§  Hypoaesthesia (reduced sense of touch)
§  Nystagmus
§  Dysgeusia
§  Balance disorder
§  Dysarthria
§  Intention tremor
§  Sedation
§  Blurred vision
§  Diplopia (double vision)
§  Visual disturbance
§  Vertigo
§  Tinnitus
§  Ear pain
§  Dyspnoea
§  Epistaxis
§  Nasal congestion
§  Rhinorrhoea
§  Vomiting
§  Constipation
§  Abdominal pain upper
§  Dyspepsia
§  Abdominal pain
§  Dry mouth
§  Stomach discomfort
§  Paraesthesia oral
§  Gastritis
§  Abdominal discomfort
§  Nephrolithiasis
§  Pollakisuria
§  Dysuria
§  Alopecia (hair loss)
§  Rash
§  Pruritus
§  Arthralgia
§  Muscle spasms
§  Myalgia
§  Muscle twitching
§  Muscular weakness
§  Musculoskeletal chest pain
§  Anorexia
§  Decreased appetite
§  Pyrexia
§  Asthenia
§  Irritability
§  Gait disturbance
§  Feeling abnormal
§  Malaise
§  Hypersensitivity
§  Bradyphrenia (slowness of thought)
§  Insomnia
§  Expressive language disorder
§  Anxiety
§  Confusional state
§  Disorientation
§  Aggression
§  Mood altered
§  Agitation
§  Mood swings
§  Anger
§  Abnormal behaviour
 
Rarely, the inhibition of carbonic anhydrase may be strong enough to cause metabolic acidosis of clinical importance.[28]
The U.S. Food and Drug Administration (FDA) has notified prescribers that topiramate can cause acute myopia and secondary angle closure glaucoma in a small subset of people who take topiramate regularly.[29] The symptoms, which typically begin in the first month of use, include blurred vision and eye pain. Discontinuation of topiramate may halt the progression of the ocular damage and may reverse the visual impairment.
 
Preliminary data suggests that, as with several other anti-epileptic drugs, topiramate carries an increased risk of congenital malformations.[30]This might be particularly important for women who take topiramate to prevent migraine attacks. In March 2011, the FDA notified healthcare professionals and patients of an increased risk of development of cleft lip and/or cleft palate (oral clefts) in infants born to women treated with Topamax (topiramate) during pregnancy and placed it in Pregnancy Category D.[23]
 
Topiramate has been associated with a statistically significant increase in suicidality,[31] and "suicidal thoughts or actions" is now listed as one of the possible side effects of the drug "in a very small number of people, about 1 in 500."[21][32]
 
Overdose
 
Symptoms of acute and acute on chronic exposure to topiramate range from asymptomatic to status epilepticus, including in patients with no seizure history.[33][34] In children, overdose may also result in hallucinations.[34] Topiramate has been deemed the primary substance that led to fatal overdoses in cases that were complicated by polydrug exposure.[35] The most common signs of overdose are dilated pupils, somnolence, dizziness, psychomotor agitation, and abnormal, uncoordinated body movements.[33][34][35]
Symptoms of overdose may include but are not limited to:[citation needed]
 
§  Agitation
§  Depression
§  Speech problems
§  Blurred vision, double vision
§  Troubled thinking
§  Loss of coordination
§  Inability to respond to things around you
§  Loss of consciousness
§  Confusion and coma
§  Fainting
§  Upset stomach and stomach pain
§  Loss of appetite and vomiting
§  Shortness of breath; fast, shallow breathing
§  Pounding or irregular heartbeat
§  Muscle weakness
§  Bone pain
§  Seizures
A specific antidote is not available. Treatment is entirely supportive.
 




注:药品如有新包装,以新包装为准。以上资讯仅供医护人员内部讨论,不作任何用药依据,具体用药指引,请咨询主治医师。

更多相关资讯:返回顶部
最新药品资讯
  • Venclyxto(维奈妥拉)联合MabThera治疗慢淋白血病,患者死亡风险降低!
  • Tagrisso(Osimertinib)在英国获批用于两种肺癌适应症的治疗
  • ziritaxestat治疗弥漫性皮肤系统性硬化症(dcSSc)2期概念验证研究成功!
  • 美国FDA批准GSK三联疗法:可同时治疗哮喘和慢阻肺
  • NBIb-1817一次性治疗帕金森病(PD)显著改善运动功能、延长ON时间
  • 口服抗生素tebipenem HBr治疗cUTI和AP关键III期临床成功,疗效不劣于ertapenem
  • 下一代选择性免疫调节剂IMU-838治疗多发性硬化症(RRMS)具有显著疗效,有良好的安全性和耐受性!
  • Fintepla(芬氟拉明)口服溶液治疗Dravet综合征相关癫痫的第三项3期研究结果:抽搐发作显著减少
  • 视神经脊髓炎谱系障碍(NMOSD)创新药Enspryng(satralizumab)获美FDA批准
  • Fasenra与标准类固醇同时治疗鼻息肉三期临床结果积极
  • Darzalex Faspro申请新适应症,治疗轻链(AL)淀粉样变性!
  • 地诺单抗(Xgeva,denosumab)治疗实体瘤骨转移疗效怎样?
  • 新药IDH1抑制剂Tibsovo治疗胆管癌效果怎么样?
  • 拜耳Nubeqa(达罗他胺)治疗非转移性去势抵抗性前列腺癌显著延长患者生存!
  • FDA对罗氏Tecentriq治疗三阴性乳腺癌研究发出警告!
  • 加码多发性硬化症!罗氏启动三项临床试验研究
  • Xeglyze说明书-价格-功效与作用-副作用
  • 赛诺菲/再生元Dupixent(达必妥®)显著延缓哮喘患者肺功能下降:疗效维持3年!
  • 默沙东止咳药gefapixant2项关键III期临床试验成功:咳嗽频率显著降低
  • Ryplazim(纤溶酶原)再次申请上市:首个先天性纤溶酶原缺乏症(C-PLGD)治疗药物!
  • 拜耳Adempas用于经PDE5i治疗反应不足的肺动脉高压(PAH)患者IV期临床成功
  • Midostaurin(米哚妥林)适应症是什么?优势在哪里?
  • 艾普利Apixaban可以在哪里买到正品?
  • 维奈妥拉/维奈托克(VENETOCLAX)怎么服用?注意事项是什么?
  • 芦可替尼Ruxolitinib治疗特应性皮炎效果好不好?
  • 巯嘌呤片(6-MP)Puri-nethol治疗急性白血病效果如何?
  • 晚期HCC患者能从Ramucirumab中获益吗?
  • 赫赛汀+拉帕替尼治疗乳腺癌效果更好
  • 欧盟批准Imfinzi(英飞凡):一线治疗广泛期小细胞肺癌(ES-SCLC)!
  • 第三代强效COMT抑制剂Ongentys(opicapone)用于治疗帕金森病(PD)的新药在日本上市!


  • 如您发现本网站有文字编辑或内容错误,请点击此处发送(需要安装有foxmail或outlook支持),


    或发邮件至:info@morecare.hk,香港济民药业感谢您的到访!


    欢迎您添加香港济民药业微信,或在公众号内留言。

    香港济民微信公众号
    • 香港济民药业友情链接
    • 友情链接

    联系我们:

    地址:
    Rm. 314, Sun Ling Plaza, 30 On Kui Street, Fanling, HONG KONG
    邮箱:
    info@pidrug.com
    电话:
    198 9654 1773
    粤ICP备17150936号
    香港济民药业官方网站
    • 关注我们 :
    • 香港济民药业微博
    • 关注香港济民药业博客
    • 香港济民药业微信公众号